User Profile
Select your user profile

Women's health

Innovative women’s health diagnostics addressing various medical needs to improve health outcomes for women across their lifespan.


Roche puts womens health diagnostics and womens health innovations firmly in the spotlight

With her today. With her for life.

Committed to women’s health diagnostics

Roche provides innovative women’s health diagnostic tests and solutions to help assess risk, identify disease, and monitor patients with specific solutions intended to meet the unique needs of women at every stage of life.

Our differentiated assay offerings on a range of technology platforms are proven to provide meaningful results and reliable decision-making information to help predict and determine next steps, and move towards more individualized patient care and disease prevention when possible.

We deliver innovations that give healthcare professionals the tools and confidence they need to support quality care for women, meeting or setting new standards for clinical guideline recommendations. Roche has diagnostic solutions, including high medical value tests, for:

  • Fertility and pregnancy
  • Polycystic Ovarian Syndrome (PCOS)
  • Prenatal testing
  • Menopause
  • Bone health
  • Breast cancer
  • Ovarian cancer
  • Cervical cancer
  • Endometrial cancer

Women all over the world should have the chance to live their best lives, and good health is an essential place to start. Roche seeks to empower women by making sure the right test is used at the right time, for well-informed decision-making.

Impacting women worldwide

Women are the backbone of most family and society ecosystems. They are a critical part of healthcare decision-making for themselves and their loved ones, yet they often face significant barriers to healthcare access and quality treatment.

Social and economic disadvantages, gender bias, and discrimination negatively impact women’s health outcomes.1 Here are some of the major health conditions and diseases that women face worldwide:

Reproductive and Sexual Health

  • Around 1 in 6 couples struggle with infertility worldwide2
  • Gestational diabetes develops in around 14.7% of pregnancies globally3
  • Preeclampsia, a serious complication which can lead to death, affects about 10% of pregnancies globally4
  • Around 8-13% of women worldwide suffer from polycystic ovary syndrome (PCOS), a hormonal disorder affecting ovulation and causing other symptoms5
  • Curable sexually transmitted infections such as gonorrhea, chlamydia, and syphilis are major causes of pelvic inflammatory disease, adverse birth outcomes, and infertility in women6

Women’s cancers

  • In 2020, there were an estimated 2.3 million cases and 685,000 deaths from breast cancer6
  • In 2020, there were 417,000 new cases of Endometrial cancer7
  • In 2020, there were an estimated 604,00 new cases and 342,000 deaths from cervical cancer8
  • In 2020, ovarian cancer caused 239,000 deaths and there were 295,000 new cases9

Infectious diseases

  • In 2021 there were 37.7 million people living with HIV globally, with women accounting for half of all new infections among adults10
  • Globally, around 257 million people are living with chronic infection of Hepatitis B and mother-to-child transmission is a major route of infection11
  • Hepatitis E is a major concern in many developing countries and can cause significant complications for pregnant women12
  • Congenital toxoplasmosis is a parasitic infection that can be passed from mother to child during pregnancy, potentially causing blindness and disability in infants13
  • Viral infection from Zika is a major concern in some regions of the world where the virus can cause microcephaly in infants14

Bone health

  • Globally osteoporosis impacts over 200 million women15

Closing the gender gap with women’s health innovations

At Roche, we are committed to bringing more innovations in women’s health diagnostics, regardless of where a woman lives or where she is from. Every woman deserves to have full control over her health, sexual and reproductive choices and should feel empowered to take an active and informed role in her own wellness, from prevention through to treatment.

Today, women are faced with inequities in treatment and care due in large part to historically insufficient research in the area of women’s health. Recognizing the critical need to overcome this disparity, Roche launched XProject, an ongoing initiative to drive meaningful change in women’s health. With the support and collaboration of key partners, Roche is conducting new research to close the health data gender gap and create a future where women have an equal opportunity to access the right information, the right diagnosis, and the right treatment.

Innovative diagnostic solutions empowering informed and precise breast cancer care.

No products found for this filter.

A powerful portfolio of screening, triage, diagnostic, and digital patient management tools to help eliminate cervical cancer 

No products found for this filter.

Roche is leading the way in providing a broad range of reliable diagnostic solutions for sexually transmitted infections (STIs), including HIV and HPV.

No products found for this filter.

Diagnostic solutions to support gynecologic and reproductive health needs.

No products found for this filter.

Comprehensive portfolio

Transforming diagnostics, empowering women

We provide diagnostic, data and insights, and support solutions that enable confident decision-making to help enhance patient care. Our assays are trusted by customers worldwide, with over 29 billion tests completed in 2023.16

From fertility, pregnancy and prenatal testing, through infectious diseases, to female cancers and bone health solutions, we truly touch women at every stage of their lives with Roche tests.

Women’s cancers17

Breast cancer: More than 6.5 million women received Roche predictive diagnostics tests to aid in breast cancer treatment decisions

Cervical cancer: More than 30 million women gained information about risk from Roche’s cervical cancer portfolio for screening and disease management

Fertility and pregnancy19

Fertility: More than 1 million women explored AMH/AMH Plus as an indication of ovarian reserve in the quest to potentially build a family

Preeclampsia: About 500,000 pregnant women were properly managed with preeclampsia ratio tests

Noninvasive prenatal testing (NIPT): Over 2 million expectant mothers were given accurate information about their babies

Closing the gap with XProject

X represents the female chromosome that warrants more investigation in order for us to achieve our goal to make a difference for the health of women. We all have an opportunity to be better.

Currently, we work with individuals, organizations, industry, government and more to identify and remove barriers in healthcare systems so that every woman can fully and equitably access care, no matter where they are in the world.

Offering medical value starts with proper clinical study enrollment, addressing patient stories of inequity, and understanding where we can best achieve our goals.

Note that we use the terms “woman” and “women” referring to people who biologically have two x chromosomes (xx). However, inclusivity is at the core of XProject and we recognize that these individuals may not all identify as female. We respect that gender identities are diverse and are striving for an equitable health system for all.

Pioneering innovation to shape a healthier tomorrow

For over 125 years, Roche has been a leading force in healthcare. Driven by a deep understanding of science and medicine, we continue to pioneer innovation to shape a healthier tomorrow. 

  • Unifying diagnostics and pharma: Under one roof, we combine the power of diagnostics and pharmaceuticals to identify the right issue with the targeted solutions from pharmaceuticals. This ensures patients receive the right treatment, at the right time.
  • Global reach, local impact: With a presence in over 150 countries, our vast network allows us to leverage innovation broadly and rapidly to deliver life-saving solutions to patients worldwide
  • Investing in what matters: We prioritize research and development (R&D) with R&D investment exceeding CHF 13.2 billion in 202318
  • Empowering people: Our innovations help clinicians to make the right choice at the right time, empower patients to have greater insights into their health and well-being, and allow payers and policymakers to utilize resources efficiently
Headshot of Kristin Garvin

We talk about taking care of a woman from an early age all the way to a mature age. Roche helps women as they go through life's progressions, because what happens in one phase will affect another.

Kristin Garvin, MPH
Integrated Marketing Manager, Women’s Health lead, Pleasanton, CA
Illustration of two female HCPs  looking at a large X, representing the x-project, Roche’s commitment to women’s health

XProject: Roche’s commitment to women

XProject is a long-term commitment and ongoing initiative aimed at closing the gaps in women’s health through partnerships, funding, and action, leading to better health outcomes for everyone. See how you can join or help support this initiative.

Happy female healthcare expert discussing over chart with couple in medical clinic

Prenatal screening for Expecting Parents

We offer a portfolio of prenatal diagnostics for checking in on the in-utero baby, including a blood test that can non-invasively define the risk of chromosomal abnormalities.

Contact us

Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.

Form Successfully Submitted!
Thank you for your submission!
text

References:

  1. American Psychological Association. Fact Sheet: Women and Socioeconomic Status. [Internet; cited 2024 June 5]. Available from: https://www.apa.org/pi/ses/resources/publications/women
  2. Njagi P. et al. Human Reproduction Open, Volume 2023, Issue 2, 2023, hoad007.
  3. Saeedi M. et al.. Increasing prevalence of gestational diabetes mellitus when implementing the IADPSG criteria: A systematic review and meta-analysis. Diabetes Res. Clin. Pract. 2021;172:108642.
  4. Bokuda, K. and Ichihara, A. Preeclampsia up to date—What’s going on?. Hypertens Res 46, 1900–1907 (2023).
  5. Bozdag, G. et al.. (2016). The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Human reproduction (Oxford, England), 31(12), 2841–2855.
  6. World Health Organization. Sexually Transmitted Infections–Fact Sheet. [Internet; cited 2024 July 15] Available from: https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)
  7. Arnold, M. et al. (2022). Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast (Edinburgh, Scotland), 66, 15–23.
  8. Crosbie, E. et al. (2022). Endometrial cancer. Lancet (London, England), 399(10333), 1412–1428.
  9. Singh, D. et al. (2023). Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. The Lancet. Global health, 11(2), e197–e206.
  10. Cabasag CJ. et al. Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020. Int J Cancer. 2022 Nov 1;151(9):1535-1541.
  11. UNAIDS. Global HIV & AIDS statistics — Fact sheet. [Internet; cited 2024 June 5] Available from: https://www.unaids.org/en/resources/fact-sheet
  12. Khue, P. et al. (2020). Hepatitis B Infection and Mother-to-Child Transmission in Haiphong, Vietnam: A Cohort Study with Implications for Interventions. BioMed research international, 2020, 4747965.
  13. Wen, G. et al. (2023). Prevalence of Hepatitis E Virus and Its Associated Outcomes among Pregnant Women in China. Pathogens (Basel, Switzerland), 12(9), 1072.
  14. Bollani L. et al. Congenital Toxoplasmosis: The State of the Art. Front Pediatr. 2022 Jul 6;10:894573.
  15. World Health Organization. Zika Virus. [Internet; cited 2024 June 5] Available from: https://www.who.int/news-room/fact-sheets/detail/zika-virus
  16. Shen Y. et al. The Global Burden of Osteoporosis, Low Bone Mass, and Its Related Fracture in 204 Countries and Territories, 1990-2019. Front Endocrinol (Lausanne). 2022 May 20;13:882241.
  17. Roche annual report. 2023. [Internet; cited 2024 May 2] Available from roche.com/investors/annualreport23.
  18. Roche Diagnostics Ltd. Data on file.
  19. Roche Diagnostics Ltd. Data on file.
  20. Roche. 2024. [Internet; cited 2024 May 2] Available from www.roche.com/innovation